← Eichor
Study identifier: NCT02828592 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Condition: Severe Aplastic Anemia  ·  Sponsor: Northside Hospital, Inc.

PhasePhase 2
Planned participants20
Who can joinAll sexes, 1 Year to 75 Years
Healthy volunteersNo

About this study

Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.

This description comes directly from the study's public registry record.

Talk to the study team

Melhem Solh, MD  ·  404-255-1930  ·  msolh@bmtga.com

Stacey Brown  ·  404-851-8238  ·  stacey.brown@northside.com

Always discuss trial participation with your own doctor first.

Locations (2)

Blood and Marrow Transplant Group of GeorgiaAtlanta, Georgia, United StatesRecruiting
Northside HospitalAtlanta, Georgia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02828592